The Antibody Drug Conjugates Market is being driven by Growing prevalence of cancer and other diseases
The Antibody Drug Conjugates Market is expected to grow at a CAGR of 16.8% during 2024 and 2029. During this period, the market is also expected to show a growth of USD 13131.4 million. The global antibody drug conjugates (ADC) market is experiencing significant growth due to the increasing acceptance and development of targeted therapies in the pharmaceutical industry. ADCs are a type of biopharmaceutical medication that utilize monoclonal antibodies to target cancer cells specifically with cytotoxic agents. This targeted approach has gained attention from pharmaceutical companies and medical experts as it shows promise in treating various types of cancer. The advancements in proteomics and genomics have enabled scientists to identify specific molecular targets that contribute to cancer cell growth and survival, further fueling the adoption of ADCs in cancer treatment.
Get more information on Antibody Drug Conjugates Market by requesting a sample report
The market is segmented based on
According to Technavio, There are several factors that are causing the market to flourish during the forecast period, which are as follows:
However, the market also witnesses some limitations, which are as follows:
Rich Experience: 20+ years leading global market research, trusted insights across industries.
Unlock Business Potential with Technavio: Maximize ROI with Technavio's tailored market research: deep dives and actionable insights.
Your Guide to Market Success: Empower your business with Technavio's market research and future-proof your decisions.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
189 |
|
Base year |
2024 |
|
Historic period |
2019-2023 |
|
Forecast period |
2025-2029 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 16.8% |
|
Market growth 2025-2029 |
USD 13131.4 million |
|
Market structure |
market_structure.ucfirst |
|
YoY growth 2024-2025(%) |
15.3 |
|
Key countries |
US, Germany, China, UK, Canada, US, Germany, China, UK, Canada, India, Japan, South Korea, France, and Italy |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Find out which segment is leading the market by accessing the free PDF report
Antibody Drug Conjugates (ADCs) refer to a class of biopharmaceutical drugs where drugs are linked to antibodies, polypeptides, proteins, lipids, polymers, or carbohydrates through a linker. This process, known as protein-drug conjugation or antibody-drug conjugation for ADCs, enhances the therapeutic effect of cytotoxic drugs by targeting them to surface antigens on tumor cells. ADCs can be classified into monoclonal antibodies, multi-specific antibodies, and polymer-drug conjugates. The use of prodrugs, such as chemotherapy agents, in ADCs improves their pharmacokinetics and reduces side effects. Immunotherapy, including angiogenesis inhibitors, is a promising application for ADCs.
In the expansive landscape of the global pharmaceuticals market, Antibody Drug Conjugates (ADCs) represent a significant segment, encompassing entities involved in the research and development (R&D) or manufacturing of these innovative therapeutics. ADCs are produced by conjugating drugs, such as cytotoxic agents, to carriers like proteins, polypeptides, lipids, polymers, or carbohydrates. This union results in Prodrugs, which are inactive until they reach their target site, ensuring enhanced efficacy and reduced side effects. The burgeoning demand for ADCs can be attributed to several factors. The aging population is a key driver, as the number of individuals aged 60 and above is projected to surge significantly. By 2050, approximately one-quarter of the US population and a similar population ratio in Europe are expected to be over 60 years old. This demographic shift will fuel the need for advanced therapeutics to address age-related health issues. Moreover, the increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, necessitates the development of targeted and effective treatments. ADCs offer a promising solution, as they enable precise drug delivery to specific cells or tissues, thereby minimizing off-target effects and improving patient outcomes. Technavio, a leading market research firm, projects that the global healthcare market, which covers the revenue generated by manufacturers and providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services, will experience substantial growth. The global pharmaceuticals sector, in particular, is expected to benefit from this trend, as ADCs represent a lucrative and rapidly evolving segment within this market.. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
Safe and Secure SSL Encrypted
One user only.
Quick & easy download option
Unlimited user access (Within your organization).
Complimentary Customization Included
*For Enterprise license, go to checkout page
Get the report (PDF) sent to your email within minutes.
